Transthyretin Amyloidosis Clinical Trial
— TTR-SNCOfficial title:
A Comprehensive Retrospective Study of Cerebral MRI Anomalies in Mutated Transthyretin Amyloidosis Patients
Verified date | September 2022 |
Source | Centre Hospitalier Universitaire de Nimes |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Transthyretin amyloidosis (aTTR) initially described as a rare disease, became the most serious hereditary polyneuropathy of adult onset and family screening has made it possible to identify and follow up many asymptomatic patients and carriers of the mutation in the TTR gene. Considered as a systemic disease with involvement of target organs (the heart, the eye, the kidney and peripheral nervous system), it seems to be more complex for neurologists according to recent publications raising the issue of central nervous system involvement. Indeed, TTR amyloid deposits seem to be correlated with the duration of the disease. These deposits can cause cortical damage by different mechanisms: direct TTR toxicity or as a result of pathology related to cerebral amyloid angiopathy (intraparenchymal or subarachnoid hematomas, small infarcts, hemosiderin). A small number of mutations in the TTR gene cause a rare phenotype of systemic amyloidosis, the oculoleptomeningeal form, characterized by clinical neurological symptoms: progressive dementia, epilepsy, ataxia, spastic paraparesis, stroke-like episodes. Hypothesis of the work: the central nervous system involvement is probably underestimated on the radiological description in patients with TTR mutation.
Status | Completed |
Enrollment | 36 |
Est. completion date | May 31, 2022 |
Est. primary completion date | May 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - patients followed at the University Hospital of Nîmes between 2017 and 2021 for a TTR neuropathy with proven mutation, having benefited from a brain MRI. Exclusion Criteria: - Patients without TTR neuropathy with proven mutation, or who did not have a brain MRI. |
Country | Name | City | State |
---|---|---|---|
France | CHU de Nîmes | Nîmes |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire de Nimes |
France,
Charidimou A, Gang Q, Werring DJ. Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum. J Neurol Neurosurg Psychiatry. 2012 Feb;83(2):124-37. doi: 10.1136/jnnp-2011-301308. Epub 2011 Nov 5. Review. — View Citation
Ikeda SI. [Cerebral amyloid angiopathy with familial transthyretin-derived oculoleptomeningeal amyloidosis]. Brain Nerve. 2013 Jul;65(7):831-42. Review. Japanese. — View Citation
Maia LF, Magalhães R, Freitas J, Taipa R, Pires MM, Osório H, Dias D, Pessegueiro H, Correia M, Coelho T. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings. J Neurol Neurosurg Psychiatry. 2015 Feb;86(2 — View Citation
Nakagawa K, Sheikh SI, Snuderl M, Frosch MP, Greenberg SM. A new Thr49Pro transthyretin gene mutation associated with leptomeningeal amyloidosis. J Neurol Sci. 2008 Sep 15;272(1-2):186-90. doi: 10.1016/j.jns.2008.05.014. Epub 2008 Jun 24. — View Citation
Vieira M, Saraiva MJ. Transthyretin: a multifaceted protein. Biomol Concepts. 2014 Mar;5(1):45-54. doi: 10.1515/bmc-2013-0038. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical-radiological characterization | Presence of signs of chronic bleeding on brain MRI (Yes/No) | Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03190577 -
Assessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients With Neuropathy of Unknown Aetiology
|
N/A | |
Completed |
NCT03588468 -
Expanding the Biomarkers in Familial Amyloid Neuropathy: MRI and Motor Unit Estimation by Electrophysiological Study
|
N/A | |
Completed |
NCT03591757 -
Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR)
|
Early Phase 1 | |
Recruiting |
NCT05577819 -
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
|
N/A | |
Terminated |
NCT04611204 -
Transthyretin Cardiac Amyloidosis in Patients With Idiopathic Carpal Tunnel Syndrome Referred for Release Surgery
|
||
Completed |
NCT03352089 -
Positron Emission Tomography / Magnetic Resonance Imaging in Aortic Stenosis
|
||
Recruiting |
NCT05814380 -
The Regional Scintigraphic DPD Uptake in Cardiac Transthyretin Amyloidosis.
|
||
Completed |
NCT03923920 -
Screening for Systemic Amyloidosis Via the Ligamentum Flavum
|
||
Completed |
NCT03886155 -
Cardiac Amyloidosis Screening at Trigger Finger Release
|
||
Completed |
NCT03862807 -
Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant
|
Phase 3 | |
Completed |
NCT02792790 -
Carpal Tunnel Syndrome and Amyloid Cardiomyopathy
|
||
Completed |
NCT03860935 -
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
|
Phase 3 | |
Not yet recruiting |
NCT06465810 -
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
|
||
Recruiting |
NCT04963985 -
The Effect of Tafamidis on Transthyretin Stabilization, Safety, Tolerability and Efficacy in Transthyretin Amyloid Polyneuropathy Patients
|
Phase 4 | |
Recruiting |
NCT05409833 -
Systemic Transthyretin Amyloidosis: Carpal Tunnel Syndrome in a Portuguese Population
|
||
Recruiting |
NCT05635045 -
Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR
|
Phase 2 | |
Completed |
NCT01171859 -
Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidosis
|
Phase 2 | |
Recruiting |
NCT03237494 -
TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects
|
||
Recruiting |
NCT04899180 -
Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis
|
Early Phase 1 | |
Recruiting |
NCT06345235 -
New Biomarkers and Plasma Prothrombotic Potential in Cardiac Transthyretin Amyloidosis
|